A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients

American Journal of Transplantation

Volumn 7, Issue 12, 2007, Pages 2704-2711

  Takemoto, S K ^a   Pinsky, B W ^a   Schnitzler, M A ^a   Lentine, K L ^a   Willoughby, L M ^a   Burroughs, T E ^a   Bunnapradist, S ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Compliance; Diabetes; Graft survival; Infections; Kidney transplantation; Medication possession ratio; Mycophenolate mofetil; Rejection

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL DISEASES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; INSURANCE CLAIM REVIEW; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MEDICARE; MIDDLE AGED; MYCOPHENOLIC ACID; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 35748956704     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01966.x     Document Type: Article

References (41)

1. Butler JA, Roderick P, Mullee M Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: A systematic review. Transplantation 2004 77 : 769 776.
2. Denhaerynck K, Dobbels F, Cleemput I et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: A literature review. Transpl Int 2005 18 : 1121 1133.
3. Jarzembowski T, John E, Panaro F et al. Impact of non-compliance on outcome after pediatric kidney transplantation: An analysis in racial subgroups. Pediatr Transplant 2004 8 : 367 371.
4. Ettenger RB, Rosenthal JT, Marik JL et al. Improved cadaveric renal transplant outcome in children. Pediatr Nephrol 1991 5 : 137 142.
5. Griffin KJ, Elkin TD. Non-adherence in pediatric transplantation: A review of the existing literature. Pediatr Transplant 2001 5 : 246 249.
6. Chisholm MA. Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs 2002 62 : 567 575.
7. Nevins TE, Kruse L, Skeans MA Thomas W. The natural history of azathioprine compliance after renal transplantation. Kidney int 2001 60 : 1565 1570.
8. De Geest S, Schafer-Keller P, Denhaerynck K et al. Supporting medication adherence in renal transplantation (SMART): A pilot RCT to improve adherence to immunosuppressive regimens. Clin Transplant 2006 20 : 359 368.
9. Butler JA, Peveler RC, Roderick P Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: A cross-sectional study. Nephrol Dial Transplant 2004 19 : 3144 3149.
10. Chisholm MA, Lance CE, Mulloy LL. Patient factors associated with adherence to immunosuppressant therapy in renal transplant recipients. Am J Health Syst Pharm 2005 62 : 1775 1781.
11. Denhaerynck K, Steiger J, Bock A et al. Prevalence and Risk Factors of Non-Adherence with Immunosuppressive Medication in Kidney Transplant Patients. Am J Transplant 2006.
12. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005 11 : 449 457.
13. Peterson AM, Nau DP, Cramer JA Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007 10 : 3 12.
14. Kasiske BL, Snyder JJ, Gilbertson D Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003 3 : 178 185.
15. Woodward RS, Schnitzler MA, Baty J et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003 3 : 590 598.
16. Hardinger KL, Brennan DC, Lowell J Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004 17 : 609 616.
17. Bunnapradist S, Lentine KL, Burroughs TE et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006 82 : 102 107.
18. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005 16 : 496 506.
19. Lentine KL, Schnitzler MA, Abbott KC et al. De novo congestive heart failure after kidney transplantation: A common condition with poor prognostic implications. Am J Kidney Dis 2005 46 : 720 733.
20. Alloway RR, Isaacs R, Lake K et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003 3 : 1211 1215.
21. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997 27 : 161 170.
22. Arns W, Cibrik DM, Walker RG et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006 82 : 1004 1012.
23. Charlson ME, Pompei P, Ales KL MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987 40 : 373 383.
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992 45 : 613 619.
25. Elixhauser A, Steiner C, Harris DR Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998 36 : 8 27.
26. Davies SJ, Phillips L, Naish PF Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002 17 : 1085 1092.
27. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995 60 : 225 232.
28. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000 69 : 2405 2409.
29. Pascual M, Theruvath T, Kawai T Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002 346 : 580 590.
30. Takemoto SK. Maintenance immunosuppression. Clin Transpl 2001 : 223 236.
31. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 2001 24 : 645 663.
32. Takemoto S, Port FK, Claas FH Duquesnoy RJ. HLA matching for kidney transplantation. Hum Immunol 2004 65 : 1489 1505.
33. Cleemput I, Kesteloot K, Vanrenterghem Y De Geest S. The economic implications of non-adherence after renal transplantation. Pharmacoeconomics 2004 22 : 1217 1234.
34. Willoughby LM, Fukami S, Bunnapradist S et al. Health insurance considerations for adolescent transplant recipients as they transition to adulthood. Pediatr Transplant 2007 11 : 127 131.
35. Kasiske BL, Cohen D, Lucey MR Neylan JF. Payment for immunosuppression after organ transplantation. American Society of Transplantation. JAMA 2000 283 : 2445 2450.
36. Chisholm MA, Vollenweider LJ, Mulloy LL et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation 2000 70 : 1240 1244.
37. Vlaminck H, Maes B, Evers G et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004 4 : 1509 1513.
38. Jassal SV, Schaubel DE, Fenton SS. Baseline comorbidity in kidney transplant recipients: a comparison of comorbidity indices. Am J Kidney Dis 2005 46 : 136 142.
39. Stirnemann PM, Takemoto SK, Schnitzler MA et al. Agreement of immunosuppression regimens described in medicare pharmacy claims with the organ procurement and transplantation network survey. J Am Soc Nephrol 2006 17 : 2299 2306.
40. Schnitzler MA, Hollenbeak CS, Cohen DS et al. The economic implications of HLA matching in cadaveric renal transplantation. N Engl J Med 1999 341 : 1440 1446.
41. Machnicki G, Pinsky B, Takemoto SK et al. Application of diagnostic classification algorithms to identify the most common causes of post-transplant complications. In : Cecka J, Terasaki P (eds). Clinical Transplants 2006. Los Angeles : UCLA Immunogenetics Center, 2006 : 57 67.